ProGenis Pharmaceuticals is delighted to announce the appointment of Professor Bu Yeap as its new Clinical Advisor for Metabolic Diseases. A distinguished clinician and researcher in endocrinology, Professor Yeap brings extensive expertise in the study and treatment of hormonal disorders and metabolic health.
Currently serving as a Professor at the Medical School of The University of Western Australia and a Consultant Endocrinologist at Fiona Stanley Hospital in Perth, Professor Yeap has dedicated his career to improving outcomes for patients with diabetes and metabolic conditions. His research explores the intricate relationships between hormones, diabetes, and cardiovascular risk, helping shape new approaches to treatment and care.
Professor Yeap’s impact on endocrinology is evident through his prolific contributions to scientific literature, with 291 published papers, including 236 original research articles. His leadership in the field was further demonstrated during his tenure as President of the Endocrine Society of Australia from 2020 to 2022, where he played a pivotal role in advancing endocrine research and clinical practice.
At ProGenis Pharmaceuticals, Professor Yeap’s insights will be instrumental in guiding our research and development efforts in metabolic health. His expertise will enhance our mission to drive innovation in endocrinology and improve patient outcomes across Australia and beyond.
We are honoured to welcome Professor Bu Yeap to our advisory team and look forward to his contributions as we continue to redefine the future of metabolic disease management.